Calcium channel blocker-induced parkinsonism: Clinical features and comparisons with Parkinson's disease

Parkinsonism and Related Disorders

Volumn 4, Issue 4, 1998, Pages 211-214

  García Ruiz, Pedro J ^a   Javier Jiménez Jiménez, Félix ^b   García De Yébenes, Justo ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Calcium channel blockers; Cinnarizine; Flunarizine; Parkinsonism; Tardive tremor

Indexed keywords

AMANTADINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINNARIZINE; FLUNARIZINE; LEVODOPA; PRIMIDONE;

ADULT; AGED; AKINESIA; ARTICLE; CLINICAL FEATURE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; TREMOR;

EID: 0344389023     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(98)00032-7     Document Type: Short Survey

References (25)

1. Martí-Masso J.F., Carrera N., De la Puente E. Posible parkinsonismo por cinarizina. Med Clin (Barc). 85:1985;614-616.
2. Chouza C., Caamaño J.L., Aljanati R., Scarameli A., De Medina D., Romero S. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet. 1:1986;1303-1304.
3. D'Alessandro R., Benassi G., Morganti G. Side effects of flunarizine. Lancet. 2:1986;464.
4. Mangone C.A., Herskovits E. Extrapyramidal and depressive reactions with flunarizine and cinnarizine. J Neurol Neurosurg Psychiatry. 52:1989;288-289.
5. Micheli F.E., Fernández Pardal M., Giannaula R., Gatto M., Casas-Parera I., Paradiso G., Torres M., Pikielni R., Fernández-Pardal J. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord. 2:1989;139-146.
6. Martí-Masso J.F., Carrera N. Calcium channel blockers and parkinsonism. Neurology. 39(suppl 1):1989;230.
7. Dick R.S., Barold S.S. Diltiazem induced parkinsonism. Am J Med. 87:1989;95-96.
8. Giménez-Roldan S., Mateo D. Cinnarizine induced parkinsonism: susceptibility related to aging and essential tremor. Clin Neuropharmacol. 14:1989;156-164.
9. García-Ruiz P.J., García de Yébenes J., Jiménez-Jiménez F.J., Vázquez A., García-Urra D., Morales B. Parkinsonism associated with calcium channel blockers: A prospective follow up study. Clin Neuropharmacol. 15:1992;19-26.
10. García-Albea E., Jiménez-Jiménez F.J., Ayuso-Peralta L., Cabrera-Valdivia F., Vaquero A., Tejeiro J. Parkinsonism unmasked by verapamil. Clin Neuropharmacol. 16:1993;263-265.
11. Negrotti A., Calzetti S. A long term follow-up study of cinnarizine and flunarizine-induced parkinsonism. Mov Disord. 12:1997;107-110.
12. Jiménez-Jiménez F.J., García-Ruiz P.J., Molina J.A. Drug-induced movement disorders. Drug Saf. 16:1997;180-204.
13. García Ruiz P.J., Mena M.A., Peñafiel N., García de Yébenes J. Cinnarizine induced parkinsonism in primates. Clin Neuropharmacol. 15:1992;152-154.
14. Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Golstein M, editors. Recent developments in Parkinson's disease, Vol 2. Florham Park, New York: MacMillan, 1987: 153-163.
15. Koller W.C. How accurately can Parkinson's disease be diagnosed? Neurology. 42(suppl 1):1992;6-16.
16. Stacy M., Jankovic J. Tardive tremor. Mov Disord. 1:1992;53-57.
17. Jankovic J. Tardive syndromes and other drug-induced movement disorders. Clin Neuropharmacol. 18:1995;197-214.
18. De Vries D.J., Beart P.M. Competitive inhibition of (3H) spiperone binding to D2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations. Eur J Pharmacol. 106:1985;133-139.
19. Mena M.A., Garcia de Yébenes M.J., Tabernero C., Casarejos M.J., Pardo B., Garca de Yébenes J. Effect of calcium antagonists on the dopamine system. Clin Neuropharmacol. 18:1995;410-426.
20. Veitch K., Hue L. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism. Mol Pharmacol. 45:1994;158-163.
21. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., Parker D. Neuroleptic medication inhibit complex I of the electron transport chain. Ann Neurol. 33:1993;512-517.
22. Rajput A.H., Rozdilsky B., Hornykiewicz O., Shannak K., Lee T., Seeman P. Reversible drug induced parkinsonism. Clinicopathologic study of two cases. Arch Neurol. 39:1982;644-646.
23. Bocola V., Fabbrini G., Sollecito A., Paladini C., Martucci N. Neuroleptic induced parkinsonism: MRI findings in relation to clinical course after withdrawal of neuroleptic drugs. J. Neurol Neurosurg Psychiatry. 60:1996;213-216.
24. Thompson P.D., Marsden C.D. Gait disorders of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord. 2:1987;1-7.
25. FitzGerald P.M., Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 4:1989;249-260.